Breast metastases from extramammary tumors are much less common than primary breast tumors and are usually due to melanoma, lymphoma, or leukemia. Metastases to the breast from renal cell carcinoma (RCC) are very rare. Here we report on a case of solitary breast metastasis from RCC, which occurred 2 years after nephrectomy.
Case presentation
A 57-year-old woman was found to have an impalpable breast mass on enhanced computerized tomography (CT) at a follow-up visit. Two years ago, she underwent a right radical nephrectomy for RCC, and shortly thereafter, she underwent total pancreatectomy. The pathological findings revealed renal clear cell carcinoma, pT1bN0M0, and a pancreatic neuroendocrine tumor (NET). There was no further treatment, and the patient was followed up with annual CT and routine blood tests. Laboratory findings, including the tumor markers carcinoembryonic antigen (CEA) and carbohydrate-associated (CA) 19-9 antigen, were almost within normal limits. Two years after surgery, CT revealed an enhanced, solitary, 0.8-cm mass, which was located in the internal part of the left breast with no physical finding. It was not associated with the enlargement of the ipsilateral axillary lymph nodes (Fig. 1) . The differential diagnosis included primary breast cancer or breast 
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Urology Case Reports metastasis from RCC or the pancreas, prompting a breast surgery consultation. Breast ultrasound (US) revealed a hypoechoic homogeneous mass, and color Doppler US demonstrated abundant peripheral vascularity. Core needle biopsy revealed that the tumor was composed of cells with clear cytoplasm. As a result, breast metastasis from RCC was considered. The patient underwent metastasectomy without dissection of axillary lymph nodes. The metastasectomized specimen contained a whitish, well-defined, solid mass measuring 0.7 Â 0.6 cm (Fig. 2) . A histological examination revealed that the tumor was composed of cells with clear cytoplasm and a prominent but delicate vascular network. These findings did not support the diagnosis of NET but rather RCC as the primary site (Fig. 3A , B and C). Immunohistochemistry (IHC) was performed to investigate the breast metastatic site, i.e., primary RCC or pancreatic NET. IHC of each tissue was positive for CD-10 in the metastatic site and RCC but was negative in the pancreas (Fig. 3D, E, and F) . This pattern was consistent with clear RCC and was the same in the primary and metastatic sites. The specific marker for NET, i.e., chromogranin A, was negative in the metastatic site. For the lymphatic spread, D2-40 immunostaining of the lymphatic endothelium for cancer invasion into the renal sinus of the primary site was negative in the RCC and metastatic site. These findings supported a diagnosis of breast metastasis from RCC. The postoperative course was uneventful, and no further adjuvant treatment was received. There was no local recurrence or metastasis 1 year after metastasectomy.
Discussion
Metastases to the breast from extramammary primary malignancies are rare. In various clinical autopsy studies, the incidence of metastasis to the breast ranges from 5% to 6.6%. 1 The most frequent metastases to the breast are from malignant melanoma, lymphoma, lung cancer, and, in men, prostatic cancer. 2 Approximately 25%e 30% of patients with RCC will present with metastatic disease at the time of diagnosis. The most common sites of metastatic RCC are the lung, bone, regional lymph nodes, liver, and brain. Metastases to the breast from RCC are rare. First reported RCC metastasis to the breast in 1942, and only 25 cases have been reported in the literature. 3 Eleven of these cases presented with metastasis as the initial sign of the disease and 14, among which two were bilateral, occurred as metachronous lesions after a former nephrectomy. Metastasis of RCC occurs through hematogenous and lymphatic spread of tumor cells to distant sites, often in an unpredictable manner due to the varying lymphatic drainage of the kidney. In general, the pathway of RCC metastasis to the breast is considered to be hematogenous. 4 In order to confirm the primary site of metastasis, IHC, e.g., CD-10, for the RCC primary, pancreas, and the metastatic site, supported the diagnosis of RCC. The results were negative for the pancreas, and therefore, the primary was considered to be RCC. The primary and metastatic sites were negative for D2-40 IHC examination. Based on these results, we confirmed that the metastatic pathway to the breast from RCC was hematogenous. In this case, it was difficult to identify the primary site of metastasis because of the concurrence of RCC and pancreatic NET. "Clear" cell change is a well-described phenomenon in pancreatic NET, especially in multiple endocrine neoplasia type 1(MEN1). 5 Moreover, both RCC and pancreatic NET are clinical findings of Von Hippel-Lindau (VHL) disease, which results from a mutation of the VHL suppressor gene. 5 In this case, the diagnostic criteria of VHL were excluded; however, we were unable to investigate mutation of the VHL gene. Mutation of the VHL gene influences carcinogenesis. Based on the patient's background, we not only had to investigate whether the pathway of metastatic spread was hematogenous or lymphatic but also whether the primary site was RCC or pancreatic NET. Finally, hematoxylin and eosin (HE) staining and IHC examination revealed that the pathway of breast metastasis was hematogenous metastasis from RCC.
Conclusions
In conclusion, isolated breast metastasis from RCC is very rare. Primary and secondary breast cancer may be clinically and radiologically similar. Breast metastasis from RCC might be considered as being hematogenous rather than lymphatic metastasis.
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